Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

HP reported for 9 months of fiscal year 2023

8/30/23 HPQ

Uralskaya Kuznitsa reported for 6 months of 2023 by IFRS

8/30/23 URKZ

PIK reported for 6 months of 2023 by RAS

8/30/23 PIKK

UTair reported for 6 months of 2023 by IFRS

8/30/23 UTAR

Bashneft reported for 6 months of 2023 by IFRS

8/30/23 BANE

Bashneft reports for 6 months of 2023 by RAS

8/30/23 BANE

Rosneft reported for 6 months of 2023 by IFRS

8/30/23 ROSN

Rosneft reported for 6 months of 2023 by RAS

8/30/23 ROSN

Nizhnekamskshina reported for 6 months of 2023 by IFRS

8/29/23 NKSH

PhosAgro reports for 6 months of 2023 by IFRS

8/29/23 PHOR